Dr. Prince is a Resident Physician in Medical Genetics and Genomics at the University of Calgary, focusing on gene-editing therapies for rare pediatric immune disorders. He currently serves as a co-investigator for the CAHN-EDIT-CD3δ project, developing an adenine base-editing treatment for CD3δ Severe Combined Immunodeficiency (SCID). Bradley’s responsibilities include clinical trial design, grant strategy, and interdisciplinary coordination—often finding himself as comfortable discussing budgets as base pairs.

Bradley is particularly motivated by the potential to create scalable, minimally toxic therapies tailored specifically for underserved Canadian communities, such as Mennonite, Hutterite, and First Nations populations. He envisions accessible, practical gene therapies becoming a reality within Canada's public healthcare framework.

Away from genetics and clinical trials, Bradley is the proud father of two young daughters, whose curiosity and energy constantly reinforce his commitment to improving the lives of children affected by rare diseases. Whether in the lab, clinic, or playground, Bradley is quietly driven by the goal of turning promising science into meaningful outcomes for families.